Please make sure that you select the correct MabThera® (rituximab) formulation and strength

SUBCUTANEOUS INJECTION

MabThera 1400 mg
ONLY FOR USE IN NHL*



Pink flip-off cap

Withdraw directly from vial and administer by subcutaneous injection

INTRAVENOUS INJECTION

MabThera 100 mg concentrate for solution for infusion
MabThera 500 mg concentrate for solution for infusion
For use in all MabThera-approved indications*



Dilute with 0.9% NaCl or 5% glucose and administer by intravenous infusion

Check for the specific MabThera SC packaging characteristics before use:

Red labelling: '**Only for subcutaneous use**', '**solution for subcutaneous injection**' and '**subcutaneous**'

MabThera SC is not indicated as once-weekly monotherapy in patients with relapsed/refractory follicular lymphoma

*NHL = non-Hodgkin's lymphoma.

Please refer to the MabThera Summary of Product Characteristics for further information: www.medicines.org.uk or www.medicinesauthority.gov.mt See overleaf for how to use the peel-off part of the label

Published by Roche Products Limited

RXUKMABO00884e

Date of Preparation: March 2017

Use the peel-off part of the label to ensure the correct formulation and strength is administered to your patient, as illustrated below

MabThera 1400 mg solution for subcutaneous injection
ONLY FOR USE IN NHL*









1. The MabThera 1400 mg vial label has a removable part

2. Remove the peel-off part

3. Stick the peel-off part on to the syringe

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal. Adverse events should also be reported to Roche Products Limited. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44(0)1707 367554.

As MabThera is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

Published by Roche Products Limited

RXUKMABO00884e
Date of Preparation: March 2017

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks